Heghine Khachatryan: Toward Personalized Management of Glanzmann Thrombasthenia
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared Journal of Thrombosis and Haemostasis (JTH)’s post on LinkedIn, adding:
“The development of antiplatelet antibodies in Glanzmann thrombasthenia remains one of the most clinically significant challenges in the long-term management of this rare inherited platelet disorder.
Beyond increasing the risk of platelet transfusion refractoriness, alloimmunization substantially complicates perioperative care and the treatment of life-threatening bleeding episodes.
Natural history data from large multicenter cohorts are therefore invaluable for identifying patients at greatest risk, optimizing transfusion strategies, and informing individualized therapeutic approaches, including the early integration of recombinant activated factor VII and emerging non-transfusion-based therapies.
This study represents an important contribution toward a more evidence-based and personalized management paradigm for patients with Glanzmann thrombasthenia.”
Journal of Thrombosis and Haemostasis (JTH) shared a post on LinkedIn about a recent article by Dominique Desprez et al., adding:
“Natural history of antiplatelet antibody formation in patients with Glanzmann thrombasthenia: a French multicenter prospective study
In 55 GT patients, anti-αIIbβ3 antibodies developed in 36%—mostly transient and genotype-linked—reducing fibrinogen binding but not triggering platelet damage, underscoring the value of antibody monitoring.”
Title: Natural history of antiplatelet antibody formation in patients with Glanzmann thrombasthenia: a French multicenter prospective study
Authors: Dominique Desprez, Roseline d’Oiron, Sophie Voisin, Céline Falaise, Marie-Christine Alessi, Paul Saultier, Géraldine Lavigne, Arnaud Essaydi, Marie-Joelle Apithy, Arnaud Dupuis, Valérie Goin, Yoann Huguenin, Mathieu Fiore

Other posts featuring Heghine Khachatryan and Journal of Thrombosis and Haemostasis on Hemostasis Today.
-
Nov 17, 2026, 15:26Hereditary Hemorrhagic Telangiectasia: The Molecular Connection Between Vascular Malformations and Bleeding
-
Nov 17, 2026, 14:54Cindy Neunert: Beyond Platelet Counts – Addressing Fatigue and Whole-Person Care in ITP
-
Nov 17, 2026, 14:44Strengthening Haemophilia Diagnosis Through Hands-On Laboratory Training – IAHAD
-
Nov 17, 2026, 14:40Platelet Membrane Protrusions Beyond Their Role in Hemostasis – JTH
-
Nov 17, 2026, 14:10Wolfgang Miesbach: Aspirin vs Anticoagulants – Who Needs More Than Aspirin?
-
Nov 17, 2026, 14:08Chaza Alaji: Soluble Transferrin Receptor – A Key to Uncovering Hidden Iron Deficiency
-
Nov 17, 2026, 14:03Shadi Tabibian: Fibrinogen – From Molecular Structure to Clinical Decision Making
-
Nov 17, 2026, 13:54Gabrielle Sarlon: Breaking the Silence on Menstrual Bleeding During Anticoagulant Therapy
-
Nov 17, 2026, 13:47Ksenia Guznova Kats: Advanced Venous Stenting in May–Thurner Syndrome